课题基金 / 基金详情

RANDOM MULTIPLE DOSE PLACEBO-CONTROLLED STUDY OF ARI-509 IN DIABETIC PATIENTS

RANDOM MULTIPLE DOSE PLACEBO-CONTROLLED STUDY OF ARI-509 IN DIABETIC PATIENTS
ARI-509 在糖尿病患者中的随机多剂量安慰剂对照研究
批准号：
5218374
负责人：
MARY KORYTKOWSKI
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5218374
关键词：
aldehyde reductase blood chemistry blood glucose carbohydrate metabolism clinical research clinical trial phase I diabetes mellitus diabetes mellitus therapy dosage drug screening /evaluation erythrocytes fructose human subject human therapy evaluation nerve oxidoreductase inhibitor pharmacokinetics sorbitol

项目摘要

项目成果

MARY KORYTKOWSKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of this study is to assess the clinical safety and tolerance of ARI-509, a new aldose reductase inhibitor, in diabetic patients; to assess the pharmacokinetics of ARI-509 after multiple doses by measuring the plasma, erythrocyte (RBC) and sural nerve concentrations of ARI-509; and to assess preliminary pharmacodynamics of ARI-509 by serial measurement of sorbitol, fructose and glucose levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION 2 DIABETES (BARI 2D)
INSULIN HPN & REGULAR PREMIX RATIO 50 & 50 VS PREMIX RATIOS 70 & 30
INSULIN HPN & REGULAR PREMIX RATIO 50 & 50 VS PREMIX RATIOS 70 & 30
SEX HORMONES AS RISK FACTORS FOR HEART DISEASE IN WOMEN WITH NIDDM
海外基金